Epigenetic remodelling upon FGFR inhibition

FGFR-altered triple negative breast cancer (TNBC) develops adaptive resistance to FGFR inhibitor therapy. A new study shows that sustained FGFR inhibition causes SWI/SNF complex eviction at YAP-recruited enhancers followed by increased mTORC1 activity. Dual inhibition of YAP or mTORC1 and FGFR has a synergistic effect on tumour growth.

Automated summary

FGFR-altered triple negative breast cancer develops adaptive resistance to FGFR inhibitor therapy, but a new study shows that dual inhibition of YAP or mTORC1 and FGFR has a synergistic effect on tumor growth. This indicates a potential new approach for treating this type of cancer.